<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="598">
  <stage>Registered</stage>
  <submitdate>11/07/2005</submitdate>
  <approvaldate>11/07/2005</approvaldate>
  <nctid>NCT00120601</nctid>
  <trial_identification>
    <studytitle>Trial for the Treatment of Alcohol Dependence</studytitle>
    <scientifictitle>The Role of Pharmacotherapy in Prevention of Relapse in Alcohol Dependence</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>211177</secondaryid>
    <secondaryid>X99-0277</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Alcoholism</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Addiction</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Naltrexone
Treatment: drugs - Acamprosate

Treatment: drugs: Naltrexone


Treatment: drugs: Acamprosate


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Time (days) to relapse</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Time (days) to lapse</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Days abstinence</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Drinks per drinking day</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Biochemical measures of liver function</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Craving</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Depression</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Anxiety</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Stress</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Global physical health</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Global mental health</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Alcohol dependence according to the ICD10 criteria, with alcohol as the subject's drug
             of choice

          -  Ages 18-65

          -  Adequate cognition and English language skills to give valid consent and complete
             research interviews (as assessed by MMSE)

          -  Willingness to give written informed consent

          -  Abstinence from alcohol for between 3 and 21 days, and resolution of any clinically
             evident alcohol withdrawal</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Opiate abuse within the last one month

          -  Sensitivity to study medications or therapy with these drugs within 6 months

          -  Active major psychiatric disorder associated with psychosis or significant suicide
             risk

          -  Pregnancy or lactation

          -  Advanced decompensated liver disease (hepatocellular failure, variceal bleeding,
             ascites or encephalopathy)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Drug Health Services, Royal Prince Alfred Hospital - Sydney</hospital>
    <postcode>2050 - Sydney</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>University of Sydney</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>National Health and Medical Research Council, Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Sydney South West Area Health Service</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>South Eastern Area Health Service</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Wentworth Area Health Services</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to compare the effectiveness of two anti-craving medications,
      naltrexone versus acamprosate, in the treatment of alcohol dependence.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00120601</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Paul Haber, MBBAMDFRACP</name>
      <address>Conjoint Associate Professor</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>